Additional file 3 of Comparative real-world study of apalutamide and darolutamide in Japanese patients with non-metastatic castration-resistant prostate cancer

Additional file 3. Studies on ARPIs in Japanese patients with nmCRPC. Abbreviations: n, number of cases; ARPI, androgen receptor pathway inhibitors; nmCRPC, nonmetastatic castration-resistant prostate cancer; MFS, metastasis-free survival; PSA, prostate-specific antigen; TRAEs, treatment-related adverse events; APA, apalutamide; DARO, darolutamide; ENZ, enzalutamide; ABI, abirateron acetate; OS, overall survival; PSADT, prostate-specific antigen doubling time; PSA at initiation, prostate-specific antigen level at treatment initiation; CRPC, castration-resistant prostate cancer; NR, not reached.